PLoS ONE (Jan 2013)

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

  • Nina Shah,
  • Beatriz Martin-Antonio,
  • Hong Yang,
  • Stephanie Ku,
  • Dean A Lee,
  • Laurence J N Cooper,
  • William K Decker,
  • Sufang Li,
  • Simon N Robinson,
  • Takuya Sekine,
  • Simrit Parmar,
  • John Gribben,
  • Michael Wang,
  • Katy Rezvani,
  • Eric Yvon,
  • Amer Najjar,
  • Jared Burks,
  • Indreshpal Kaur,
  • Richard E Champlin,
  • Catherine M Bollard,
  • Elizabeth J Shpall

DOI
https://doi.org/10.1371/journal.pone.0076781
Journal volume & issue
Vol. 8, no. 10
p. e76781

Abstract

Read online

Natural killer (NK) cells are important mediators of anti-tumor immunity and are active against several hematologic malignancies, including multiple myeloma (MM). Umbilical cord blood (CB) is a promising source of allogeneic NK cells but large scale ex vivo expansion is required for generation of clinically relevant CB-derived NK (CB-NK) cell doses. Here we describe a novel strategy for expanding NK cells from cryopreserved CB units using artificial antigen presenting feeder cells (aAPC) in a gas permeable culture system. After 14 days, mean fold expansion of CB-NK cells was 1848-fold from fresh and 2389-fold from cryopreserved CB with >95% purity for NK cells (CD56(+)/CD3(-)) and less than 1% CD3(+) cells. Though surface expression of some cytotoxicity receptors was decreased, aAPC-expanded CB-NK cells exhibited a phenotype similar to CB-NK cells expanded with IL-2 alone with respect to various inhibitory receptors, NKG2C and CD94 and maintained strong expression of transcription factors Eomesodermin and T-bet. Furthermore, CB-NK cells formed functional immune synapses with and demonstrated cytotoxicity against various MM targets. Finally, aAPC-expanded CB-NK cells showed significant in vivo activity against MM in a xenogenic mouse model. Our findings introduce a clinically applicable strategy for the generation of highly functional CB-NK cells which can be used to eradicate MM.